- Home
- GLRE vs DRTS Comparison
GLRE vs DRTS Comparison
Compare GLRE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | DRTS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Cayman Islands | Israel |
| Employees | N/A | 125 |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 546.5M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLRE | DRTS |
|---|---|---|
| Price | $16.76 | $6.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 177.0K | ★ 227.4K |
| Earning Date | 03-09-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $965.57 |
| P/E Ratio | $7.89 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $2.30 |
| 52 Week High | $17.47 | $8.60 |
Technical Indicators
Market Signals| Indicator | GLRE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 45.05 |
| Support Level | $12.66 | $6.37 |
| Resistance Level | $17.02 | $7.75 |
| Average True Range (ATR) | 0.56 | 0.42 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 74.83 | 25.00 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.